In addition to PD-L1 and MSI status, TMB, a measure of mutations per megabase (mutations/Mb) in cancer cells, has been considered predictive of the response to immunotherapy, on the basis that tumors with a high TMB present a higher amount of neoantigens and have more susceptibility to creating an immune response. The gene discussed is CD274; the disease is cancer.